

FORM PTO-1449 LIST OF PATENTS AND OTHER ITEMS FOR APPLICATION INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		ATTY. DOCKET NO. 266/186	SERIAL NO. 09/929,546
		APPLICANT: Neil H. Bander	
		FILING DATE: August 13, 2001	GROUP: 1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
GW	AA	4,814,275	3/21/1989	DURDA ET AL.	435	240.27	5/13/1985
GW	AB	4,863,851	9/5/1989	McEWAN ET AL.	435	7	10/20/1986
GW	AC	4,863,854	9/5/1989	MATTES ET AL.	435	7	8/12/1985
GW	AD	5,013,645	5/7/1991	KIM	435	7.92	3/23/1988
GW	AE	5,118,611	6/2/1992	SMITH ET AL.	435	7.23	10/3/1988
GW	AF	5,162,504	8/10/1992	HOROSZEWICZ	530	388.2	6/3/1988
GW	AG	5,227,471	7/13/1993	WRIGHT, JR.	530	388.8	1/30/1992
GW	AH	5,229,289	7/20/1993	KJELDSSEN ET AL.	435	240.27	12/16/1991
GW	AI	5,314,996	5/24/1994	WRIGHT, JR.	530	387.3	7/13/1993
GW	AJ	5,342,924	8/30/1994	CHANG	530	387.9	7/9/1993
GW	AK	5,489,525	2/6/1996	PASTAN	435	7.23	10/8/1992
GW	AL	5,538,866	7/23/1996	ISRAELI ET AL.	435	69.3	10/18/1994
GW	AM	5,599,677	2/4/1997	DOWELL ET AL.	435	7.4	12/29/1993
GW	AN	5,855,866	1/5/1999	THORPE ET AL.	424	1.49	03/02/1994
GW	AO	5,877,289	3/2/1999	THORPE ET AL.	530	387.1	06/07/1995

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES	NO
GW	AP	WO 00/50457 (PCT/US99/26844)	8/31/2000 (11/11/1999)	PCT	—	—		
GW	AQ	WO 99/43710 (PCT/US99/03810)	9/2/1999 (02/22/1999)	PCT	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

GW	AR	Chang et al., "Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature," <i>Cancer Res.</i> , 59:3192-3198 (1999)
----	----	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EXAMINER:


GW

DATE CONSIDERED:

7/21/03


EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

FORM PTO-1449	ATTY. DOCKET NO. 266/186	SERIAL NO. 09/929,546
LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		
APPLICANT: Neil H. Bander		GROUP: 1642
FILING DATE: August 13, 2001		
(Use several sheets if necessary)		




AS	Coleman et al., "Fundamental Immunology," Wm. C. Brown Publishers, pg. 76
AT	Harlow et al., "Antibodies: A laboratory manual", Cold Spring Harbor Laboratory, pgs. 139-243
AU	Heston, "Characterization and Glutamyl Preferring Carboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase" (<u>Urology</u> 49 (Supp. 3A): 104-112; 106 (1997)
AV	Horoszewicz et al. "Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients," <u>Anticancer Research</u> , 7:927-936 (1987)
AW	Israeli et al., "Expression of the Prostate-Specific Membrane Antigen", <u>Cancer Research</u> , 54:1807-1811 (1994)
AX	Israeli et al., "Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen", <u>Cancer Research</u> , 53:227-230 (1993)
AY	Jain, R.K. "Vascular and interstitial barriers to delivery of therapeutic agents in tumors" <u>Cancer and Metastasis Reviews</u> , Vol. 9, p. 253-266
AZ	Liu, et al., "Constitutive and Antibody-Induced Internalization of Prostate-Specific Membrane Antigen," <u>Cancer Res.</u> 58:4055-60 (1998)
BA	Liu, et. al., "Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen also React with Tumor Vascular Endothelium," <u>Cancer Res.</u> 57:3629-34 (1997)
BB	Murphy et al., "Measurement of Prostate-Specific Membrane Antigen in the Serum With a New Antibody," <u>The Prostate</u> , 28:266-271 (1996)
BC	Rochon et al., "Western Blot Assay for Prostate-Specific Membrane Antigen in Serum of Prostate Cancer Patients," <u>The Prostate</u> , 25:219-223 (1994)
BD	Schlom, "Monoclonal antibodies: They're more and less than you think", in <u>Molecular Foundations of Oncology</u> , ed. by Broder, William & Wilkins
BE	Silver et al., "Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues," <u>Clin. Cancer Res.</u> 3:81-85 (1997)
BF	Troyer et al., "Biochemical Characterization and Mapping of the 7EII-C5.3 Epitope of the Prostate-Specific Membrane Antigen," <u>Urol Oncol.</u> , 1:29-37 (1995)
BG	Troyer et al., "Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids," <u>Int. J. Cancer</u> , 62:552-558 (1995)
BH	Troyer et al., "Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line," <u>Prostate</u> , 30:232-242. (1997)
BI	Wright et al., "Expression of Prostate-Specific Membrane Antigen in Normal, Benign, and Malignant Prostate Tissues," <u>Urol Oncol.</u> , 1:18-28 (1995)
BJ	Yang et al., AACR Abstract #2996 (1998); "Alpha particle emitter therapy of micrometastases: ²¹³ Bi-J5.....(anti-PSMA) treatment of LNCaP spheroids," <u>Proceedings of the American Association for Cancer Research</u> , 39:440 (1998).
BK	Dillman R.O et al., "Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal Antibodies" <u>Cancer Biotherapy</u> , 9(1):17-28 (1994)
BL	Dillman et al., "Toxicities associated with monoclonal antibody infusions in cancer patients." <u>Molecular Biother</u> , 1:81-85 (1988)
BM	Leung, J., et al., "Selection of a monoclonal antibody to a new prostate cancer marker for in vivo clinical trials" (abstract) 6 th Int. Congr. Immunol., p. 516 (1986)
BN	Wang et al., "Monoclonal Antibody Assays for Prostatic Tumor", <u>Immunol Ser</u> 39:195-219 (1988)
BO	ATCC Deposit #HB9131, dated June 24, 1986


EXAMINER: <i>Campbell</i>	DATE CONSIDERED: 8/3/03
EXAMINER/ Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	

Substitute Form PTO-1449 (Modified)  Information Disclosure Statement by Applicant (Use several sheets if necessary) 37 CFR 1.98(b)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 10448-184008	Application No. 09/929,546
	Applicant Neil H. Bander		
	Filing Date August 13, 2001	Group Art Unit	

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
BN	AA	US 4,454,106	June 12, 1984	Gansow et al.			
	AB	US 4,472,509	Sept 18, 1984	Gansow et al.			
	AC	US 4,855,353	Aug 8, 1989	Kurami et al.			
	AD	US 4,885,363	Dec 5, 1989	Tweedle et al.			
	AE	US 5,053,503	Oct 1, 1991	Dean et al.			
	AF	US 5,057,302	Oct 15, 1991	Johnson et al.			
	AG	US 5,130,118	July 14, 1992	Johnson et al.			
	AH	US 5,198,208	Mar 30, 1993	Berg et al.			
	AI	US 5,208,324	May 4, 1993	Klaveness et al.			
	AJ	US 5,217,704	June 8, 1993	Johnson et al.			
	AK	US 5,419,893	May 30, 1995	Berg et al.			
	AL	US 5,474,756	Dec 12, 1995	Tweedle et al.			
	AM	US 5,531,978	July 2, 1996	Berg et al.			
	AN	US 5,565,562	Oct 15, 1996	Parker et al.			
	AO	US 5,578,484	No 26, 1996	Horoszewicz			
	AP	US 5,639,879	June 17, 1997	Mease et al.			
	AQ	US 5,660,827	Aug 26, 1997	Thorpe et al.			
	AR	US 5,674,470	Oct 7, 1997	Tweedle et al.			
	AS	US 5,697,902	Dec 16, 1997	Goldenberg			
	AT	US 5,763,202	June 9, 1998	Horoszewicz			
	AU	US 5,776,427	July 7, 1998	Thorpe et al.			
	AV	US 5,804,602	Sept 8, 1998	Slusher et al.			
	AW	US 5,846,519	Dec 8, 1998	Tweedle et al.			
	AX	US 5,863,538	Jan 26, 1999	Thorpe et al.			
	AY	US 5,935,818	Aug 10, 1999	Israeli et al.			
	AZ	US 5,958,474	Sept 28, 1999	Lee et al.			
	AAA	US 5,965,132	Oct 12, 1999	Thorpe et al.			

Examiner Signature 	Date Considered 8/4/2003
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


 Substitute Form PTO-1449
 (Modified)

 U.S. Department of Commerce
 Patent and Trademark Office

 Attorney's Docket No.
 10448-184008

 Application No.
 09/929,546

**Information Disclosure Statement
 by Applicant**

(Use several sheets if necessary)

 Applicant
 Neil H. Bander

 Filing Date
 August 13, 2001

Group Art Unit

U.S. Patent Documents

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>CN</i>	ABB	US 6,004,554	Dec 21, 1999	Thorpe et al.			
	ACC	US 6,004,555	Dec 21, 1999	Thorpe et al.			
	ADD	US 6,022,524	Feb 8, 2000	Maisano et al.			
	AEE	US 6,036,955	Mar 14, 2000	Thorpe et al.			
	AFF	US 6,051,230	April 18, 2000	Thorpe et al.			
	AGG	US 6,093,399	July 25, 2000	Thorpe et al.			
	AHH	US 6,143,274	Nov 17, 2000	Tweedle et al.			
	AII	US 6,150,508	Nov 21, 2000	Murphy et al.			
	AJJ	US 6,261,535	July 17, 2001	Thorpe et al.			
	AKK	US 6,331,175	Dec 18, 2001	Goldenberg			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>CN</i>	ALL	WO 86/06384	Nov 6, 1986	PCT				
	AMM	WO 88/02635	April 21, 1988	PCT				
	ANN	WO 89/00557	Jan 26, 1989	PCT				
	AOO	WO 89/06979	Aug 10, 1989	PCT				
	APP	WO 91/15466	Oct 17, 1991	PCT				
	AQQ	WO 93/17715	Sept 16, 1993	PCT				
	ARR	WO 93/19668	Oct 14, 1993	PCT				
	ASS	WO 94/04702	March 3, 1994	PCT				
	ATT	WO 94/09820	May 11, 1994	PCT				
	AUU	WO 94/26297	Nov 24, 1994	PCT				
	AVV	WO 95/26206	Oct 5, 1995	PCT				
	AWW	WO 95/31444	Nov 23, 1995	PCT				
	AXX	WO 96/26272	Aug 29, 1996	PCT				
	AYY	WO 96/39185	Dec 12, 1996	PCT				

Examiner Signature

Date Considered

Gary B. Nutter

8/3/2003

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
10448-184008Application No.
09/929,546**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR 1.98(b))

Applicant
Neil H. BanderFiling Date
August 13, 2001

Group Art Unit

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>AW</i>	AZZ	WO 96/40245	Dec 19, 1996	PCT				
	AAAA	WO 97/32862	Sept 12, 1997	PCT				
	ABBB	WO 97/35616	Oct 2, 1997	PCT				
	ACCC	WO 00/52473	Sept 8, 2000	PCT				
	ADDD	WO 00/74729	Dec 14, 2000	PCT				
	AEEE	EP 0 208 531 B1	Jan 14, 1987	Europe				
	AFFF	EP 0 232 751 B1	Aug 19, 1987	Europe				
	AGGG	EP 0 233 619 B1	Aug 26, 1987	Europe				
	AHHH	EP 0 279 397 B1	Aug 24, 1988	Europe				
	AIII	EP 0 292 689 B1	Nov 30, 1988	Europe				
	AJJJ	EP 0 299 795 A1	Jan 18, 1989	Europe				
	AKKK	EP 0 315 188 B1	May 10, 1989	Europe				
	ALLL	EP 0 382 583 B1	Aug 16, 1990	Europe				
	AMMM	EP 0 392 423 A2	Oct 17, 1990	Europe				
	ANNN	EP 0 466 200 AW	Jan 15, 1992	Europe				
	AOOO	EP 0 495 878 B1	July 29, 1992	Europe				
	APPP	EP 0 594 739 B1	May 4, 1994	Europe				
	AQQQ	EP 0 882 454 AZ	Dec 9, 1998	Europe				

RECEIVED

JUL 24 2002

TECH CENTER 1600/2900

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
<i>AW</i>	ARRR	Barren et al. (1997), "Monoclonal Antibody 7E11.C5 Staining of Viable LNCaP Cells", Prostate 30(1):65-8.
	ASSS	Carter et al. (1996), "Prostate-specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase", Proc. Natl. Acad. Sci. U.S.A. 93:749-751.

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TECH CENTER 1600/2900

RECEIVED

Substitute Form PTO-1449

U.S. Department of Commerce
Patent and Trademark Office

Attorney's Docket No.

10448-184008

Application No.

09/929,546

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR §1.97(b))

Applicant

Neil H. Bander

Filing Date

August 13, 2001

Group Art Unit

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
GR	ATTT	Diamond et al. (1997), "Monoclonal Antibody 225 Blockade of Prostate Specific Membrane Antigen (PSM) Expression: Potential Novel Therapy for Prostate Cancer", Journal of Urology 157(4 suppl):226 (Abstract 884).
	AUUU	Fair et al. (1997), "Prostate Specific Membrane Antigen", Prostate 32(2):140-8.
	AVVV	Israeli et al. (1997), "Prostate Specific Membrane Antigen and Other Prostatic Tumor Markers on the Horizon", Urological Clinics of North America 24(2):439-50.
	AWWW	Leek et al. (1995), "Prostate-Specific Membrane Antigen: Evidence for the Existence of a Second Related Human Gene", British Journal of Cancer 72:583-588.
	AXXX	Murphy et al. (1995), "Comparison of Prostate Specific Antigen, Prostate Specific Membrane Antigen, and LNCaP-Based Enzyme-Linked Immunosorbent Assays in Prostatic Cancer Patients and Patients With Benign Prostatic Enlargement", The Prostate 26:164-168.
	AYYY	Murphy et al. (1995), "Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients", Anticancer Res. 15:1473-1480.
	AZZZ	Pinto et al. (1996), "Prostate-Specific Membrane Antigen: A Novel Folate Hydrolase in Human Prostatic Carcinoma Cells", Clinical Cancer Research 2(9):1445-51.
	AAAAA	Su et al. (1995), "Alternatively Spliced Variants of Prostate-specific Membrane Antigen RNA: Ratio of Expression as a Potential Measurement of Progression", Cancer Research 55:1441-1443.
	ABBBB	Troyer et al. (1994), "Subcellular Localization of the 7E11-C5 Prostate Specific Antigen", Proc. Am. Assoc. Cancer Research 35:283 (Abstract 1688).
	ACCCC	Uria et al. (1997), "Prostate Specific Membrane Antigen in Breast Carcinoma", The Lancet 349(9065):1601.
	ADDDD	Wright (1990), "Characterization of a New Prostate Carcinoma-Associated Marker: 7E11-C5", Antibody Immunoconjugates and RadioPharmaceuticals 3:Abstract 193.

Examiner Signature

Date Considered

EXAMINER: Initials of citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.